Q1 2019 13F Holders as of 31 Mar 2019
-
Type / Class
-
Equity / ADR
-
Shares outstanding
-
55,574,229
-
Number of holders
-
137
-
Total 13F shares, excl. options
-
45,989,019
-
Shares change
-
+5,906,750
-
Total reported value, excl. options
-
$5,412,737,939
-
Value change
-
+$716,635,309
-
Put/Call ratio
-
39%
-
Number of buys
-
88
-
Number of sells
-
-53
-
Price
-
$117.70
Significant Holders of Ascendis Pharma A/S - ADR (ASND) as of Q1 2019
168 filings reported holding ASND - Ascendis Pharma A/S - ADR as of Q1 2019.
Ascendis Pharma A/S - ADR (ASND) has 137 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 45,989,019 shares
of 55,574,229 outstanding shares and own 83% of the company stock.
Largest 10 shareholders include FMR LLC (4,692,707 shares), PRICE T ROWE ASSOCIATES INC /MD/ (4,669,002 shares), RA CAPITAL MANAGEMENT, LLC (4,132,442 shares), ORBIMED ADVISORS LLC (3,970,673 shares), BAKER BROS. ADVISORS LP (3,390,270 shares), Vivo Capital, LLC (2,046,832 shares), Avoro Capital Advisors LLC (1,795,000 shares), EVENTIDE ASSET MANAGEMENT, LLC (1,698,648 shares), FARALLON CAPITAL MANAGEMENT LLC (1,500,000 shares), and MILLENNIUM MANAGEMENT LLC (1,378,309 shares).
This table shows the top 137 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.